腹部电刺激联合气道廓清技术对神经疾病气管造口患者拔管成功率的影响:一项随机对照试验
本研究为随机、评估者盲法对照试验,纳入68例已成功脱离机械通气但仍气管造口的神经疾病成人患者,随机分为对照组和实验组各34例。两组均接受6周常规治疗联合气道廓清技术,实验组额外接受腹部电刺激。6周时实验组拔管成功率显著高于对照组(93.3% vs 73.3%,OR 5.070,95%CI 1.41-18.24,P=0.013),非自主咳嗽峰流量和腹肌厚度也显著改善,但临床肺部感染评分和静息膈肌移动度无显著差异。
要点
- 纳入68例神经疾病气管造口成人患者,均已成功脱离机械通气但仍保留气管造口,随机分为实验组和对照组各34例。
- 实验组在6周常规治疗联合气道廓清技术基础上加用腹部电刺激,拔管成功率93.3%,对照组73.3%(OR 5.070,95%CI 1.41-18.24,P=0.013)。
- 6周时实验组非自主咳嗽峰流量较对照组平均提高39.433 L/min(95%CI 28.83-50.04,P<0.001),腹肌厚度增加0.106 cm(95%CI 0.08-0.13,P<0.001)。
- 两组临床肺部感染评分(P>0.05)和静息膈肌移动度(P>0.05)无显著差异,提示该干预未改善感染控制或静息膈肌活动。
- 该干预适用于已脱机但仍气管造口的神经疾病成人患者,不适用于仍依赖机械通气或非神经疾病气管造口人群(原文未纳入)。
适用人群与场景
- 纳入标准:成人神经疾病患者,已成功脱离机械通气但仍保留气管造口,来自济宁医学院附属医院康复医学科。
- 排除标准:原文未提及。
诊断标准与关键阈值
- 拔管成功率为主要结局,原文未给出拔管的具体诊断标准或决策阈值。
- 次要结局包括非自主咳嗽峰流量、临床肺部感染评分、腹肌厚度和静息膈肌移动度,原文未给出各指标的启动或停止阈值。
处置流程与药物剂量
- 第一步:两组均接受6周常规治疗联合气道廓清技术。
- 第二步:实验组在常规治疗联合气道廓清技术基础上额外接受腹部电刺激,具体刺激参数、频率、强度、每次时长原文未提及。
- 第三步:6周后评估拔管成功率、非自主咳嗽峰流量、临床肺部感染评分、腹肌厚度和静息膈肌移动度。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究设计:随机、评估者盲法对照试验,单中心(济宁医学院附属医院康复医学科),样本量68例,实验组34例、对照组34例。
- 主要终点:6周拔管成功率实验组93.3%,对照组73.3%,OR 5.070(95%CI 1.41-18.24,P=0.013)。
- 关键次要终点:非自主咳嗽峰流量平均差39.433 L/min(95%CI 28.83-50.04,P<0.001);腹肌厚度差0.106 cm(95%CI 0.08-0.13,P<0.001)。
- 其他次要终点:临床肺部感染评分组间无显著差异(P>0.05);静息膈肌移动度组间无显著差异(P>0.05)。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:随机、评估者盲法对照试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、样本量较小(68例)、评估者盲法但干预难以对患者和治疗师设盲、随访仅6周、原文未报告不良事件。
对床旁实践的改变
- 对于已成功脱机但仍气管造口的神经疾病成人患者,可在常规治疗联合气道廓清技术基础上加用腹部电刺激,以提高6周拔管成功率。
- 该干预可改善非自主咳嗽峰流量和腹肌厚度,但不应期望其改善临床肺部感染评分或静息膈肌移动度。
- 适用人群为已脱机但仍气管造口的神经疾病成人患者;仍依赖机械通气者、非神经疾病气管造口者不在本研究纳入范围,不能外推。
- 腹部电刺激的具体参数(频率、强度、时长)原文未报告,临床实施时不能照搬本研究方案剂量。
指南或共识出处
- 原文未提及指南或共识出处;本研究发表于Crit Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to investigate the effects of combined abdominal electrical stimulation and airway clearance techniques on the primary outcome of decannulation success in tracheostomized patients with neurologic disorders.
DESIGN: A randomized, assessor-blinded, controlled trial.
SETTING: Department of Rehabilitation Medicine, Affiliated Hospital of Jining Medical University.
PATIENTS: A total of 68 adult patients with neurologic disorders who had successfully weaned off mechanical ventilation but remained tracheostomized participated in this study.
INTERVENTIONS: Airway clearance techniques with or without abdominal electrical stimulation therapy.
MEASUREMENTS AND MAIN RESULTS: We randomized 68 patients into control ( n = 34) and experimental ( n = 34) groups. Both groups received a 6-week course of conventional treatment combined with airway clearance techniques. The experimental group additionally received abdominal electrical stimulation. The primary outcome was the decannulation success rate. Secondary outcomes assessed over 6 weeks included peak flow rate during nonvoluntary coughing, clinical pulmonary infection score, abdominal muscle thickness, and resting diaphragmatic mobility. At 6 weeks, the experimental group demonstrated significantly higher peak involuntary cough flow rate (mean difference, 39.433 L/min; 95% CI, 28.83-50.04; p < 0.001) and abdominal muscle thickness (difference, 0.106 cm; 95% CI, 0.08-0.13; p < 0.001) compared with the control. Furthermore, the decannulation success rate was significantly higher in the experimental group (93.3%) than that in the control group (73.3%; odds ratio, 5.070; 95% CI, 1.41-18.24; p = 0.013). However, no significant differences were observed between the two groups in clinical pulmonary infection scores ( p > 0.05) or resting diaphragm mobility ( p > 0.05).
CONCLUSIONS: Adding abdominal electrical stimulation to airway clearance techniques significantly improves cough efficacy, increases abdominal muscle thickness, and enhances decannulation success in tracheostomized patients with neurologic disorders. However, it does not appear to alter infection control or resting diaphragmatic activity.
参考来源
- Huo F, Xu H, Shao S, et al. Effects of Abdominal Electrical Stimulation Combined With Airway Clearance Techniques in Tracheotomized Patients With Neurological Disorders: A Randomized, Controlled Trial. Crit Care Med. 2026. PMID: 42467907. doi:10.1097/CCM.0000000000007267
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。